Alejandro Pérez Alba

Alejandro Pérez Alba

Auto-generated profile, based on publicly available information

Alejandro Pérez Alba

Nephrology Department, Hospital General Universitario de Castellón, 12004 Castellón de la Plana, Spain

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2018 in Blood Purification
Verified
Journal Article
Closed access
PDF file
JRJavier Reque
Javier Reque
AAAlejandro Pérez Alba
Alejandro Pérez Alba
NPNayara Panizo
Nayara Panizo
JSJuan José Sánchez-Canel
Juan José Sánchez-Canel
MPMaria Jose Pascual
Maria Jose Pascual
RPRamón Pons Prades
Ramón Pons Prades
Background: Recent evidence suggests a better reduction rate of some uremic toxins with expanded hemodialysis (HDx). Methods: Prospective study including 8 hemodialysis patients. We divided the study in 2 phases; within the first one, we assigned 4 patients (group 1) to undergo online hemodiafiltration with a PF 210H dialyzer, and the other 4 patients (group 2) to undergo HDx with the high retention onset Theranova 500 dialyzer during 24 sessions. Later, during the second phase and after a washout period, the same patients were switched to receive HDx (group 1) and HDF (group 2). Results: No differences were found in the Urea and β2-microglobulin reduction ratio. However, in the case of myoglobin, the reduction ratio with HDF was 35 vs. 60% with HDx (p < 0.001). Similarly, in the case of prolactin, the reduction ratio with HDF was 45 and 61% with HDx (p < 0.001). Conclusions: We conclude that HDx is not inferior to online hemodiafiltration in the clearance of small and middle molecules and could be superior in the clearance of larger middle molecules.

17 May 2022 in Journal of Thyroid Research
Verified
Journal Article
Open access
PDF file
JRJavier Reque
Javier Reque
BPBeatriz Garcia Peris
Beatriz Garcia Peris
NGNayara Panizo Gonzalez
Nayara Panizo Gonzalez
AAAlejandro Perez Alba
Alejandro Perez Alba
Luis D'MarcoLuis D'Marco
Luis D'Marco
ECEladio Collado-Boira
Eladio Collado-Boira
Introduction. Renal function and thyroid metabolism are tightly related. However, evidence about subclinical hypothyroidism prevalence in patients with chronic kidney disease and its related factors is scarce. Objectives. Our aim is to analyze subclinical hypothyroidism prevalence and its related factors in patients with advanced chronic kidney disease. Materials and methods. Nondialysis-dependent patients with chronic kidney disease at stages 3 to 5 were included. Other inclusion criteria were age above 18 years and clinical stability. Patients with diagnosed thyroid illnesses were excluded. Subclinical hypothyroidism was defined as thyroid stimulating hormone (TSH) > 5.3 mU/L, with free thyroxine 4 (FT4) between 0.54 and 1.24 ng/dl. Filiation data, comorbidities, and routine blood and urine test results were registered. Results. A total of 299 patients were included. Of them, 184 (61.5%) were men. The mean age was 71 +/- 13 years old. The mean glomerular filtration rate (CKD-EPI) was 22 +/- 9 ml/min/1.73 m(2). According to chronic kidney disease stages, global distribution of patients was as follows: Stage 3, 67 patients (22.4%); Stage 4, 155 patients (51.8%); and Stage 5, 77 patients (25.8%). We found subclinical hypothyroidism in 54 (18.1%) patients. According to chronic kidney disease stages, distribution of affected patients was as follows: Stage 3, 9 patients (13%); Stage 4, 25 patients (16.1%); and Stage 5, 20 patients (26%). Differences among stages were statistically significant. By univariate analysis, factors related with subclinical hypothyroidism were as follows: age RR 1.048 (95% CI 1.019-1.078; p=0.001), hypertension RR 2.705 (95% CI 1.026-7.130; p=0.04), glomerular filtration rate RR 0.962 (95% CI 0.929-0.996; p=0.03), and proteinuria higher than 1 gram/day RR 2.387 (95% CI 1.303-4.374; p=0.005). By multivariate analysis adjusted by age, hypertension, glomerular filtration rate, proteinuria, diabetes, and cardiovascular disease history, only age RR 1.016 (95% CI 1.009-1.028; p=0.04) and glomerular filtration rate RR 0.963 (95% CI 0.930-0.997; p=0.03) preserved their independent association with subclinical hypothyroidism. Conclusions. Subclinical hypothyroidism prevalence in patients with chronic kidney disease is high and increases with renal disease severity. Factors independently related to subclinical hypothyroidism are age and glomerular filtration rate.

15 April 2020 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
APAlejandro Pérez-Alba
Alejandro Pérez-Alba
JRJavier Reque-Santiváñez
Javier Reque-Santiváñez
MVMilagros Vázquez-Gómez
Milagros Vázquez-Gómez
RPRamón Pons-Prades
Ramón Pons-Prades

1 November 2017 in Nefrología
Verified
Journal Article
Open access
AAAlejandro Pérez Alba
Alejandro Pérez Alba
FRFernanda Slon Roblero
Fernanda Slon Roblero
SGSandra Castellano Gasch
Sandra Castellano Gasch
MRM. Auxiliadora Bajo Rubio
M. Auxiliadora Bajo Rubio

1 January 2012
Verified
Journal Article
Closed access
JSJuan J Sánchez-Canel
Juan J Sánchez-Canel
RPRamón Pons-Prades
Ramón Pons-Prades
MSM Laura Salvetti
M Laura Salvetti
ASAlejandro Seores
Alejandro Seores
MVMilagros Vázquez
Milagros Vázquez
JVJuan Villatoro
Juan Villatoro

23 September 2024 in Kidney and Dialysis
Verified
Journal Article
Open access
PDF file
HPHugo Vergara Pérez
Hugo Vergara Pérez
AAAlejandro Pérez Alba
Alejandro Pérez Alba
PBPablo Baliño
Pablo Baliño
APAsunción Rius Peris
Asunción Rius Peris
JRJavier Reque
Javier Reque
Background: Historically, a large gender-related disparity in vascular access (VA) has been demonstrated, with there being a lower prevalence of women with arteriovenous fistula (AVF) compared to men, and women have worse maturity rates. The cause of this difference is not entirely clear, although several reasons that could contribute to it have been hypothesized. The emergence of new percutaneous FAV (pFAV) systems could be an alternative for reducing these differences. Objective: This study aims to determine whether there is a gender difference in the creation of AVFs using new percutaneous systems. Material and Methods: A systematic review of the literature was conducted by searching PubMed and Google Scholar using the following terms: “percutaneous arteriovenous fistula”, “endovascular arteriovenous fistula”, and “hemodialysis”. All clinical trials, comparative studies, and descriptive studies involving patients who underwent a pAVF were included. Results: Finally, the review includes 19 studies, comprising 14 retrospective studies and 5 prospective studies. Of these, six studies are comparative, five of which compare pAVFs with surgically created AVFs (sAVFs), and one compares pAVFs performed using different systems with each other. A total of 1269 patients were included in the review. Of the total number of patients, only 414 were women, representing 32.62% of patients. Conclusions: The number of women included in the various studies analyzing pAVF remains very low, representing less than one-third of all patients. Although the causes of this difference are not entirely clear, several reasons have been hypothesized, such as socioeconomic factors, anatomical factors, or even patients’ preferences. Given these results, further studies are needed to try to clarify the reasons for this gender disparity and to establish different strategies to mitigate the barriers faced by women in accessing AVFs.